Welcome to our dedicated page for VISKASE HOLDINGS SEC filings (Ticker: ENZND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VISKASE HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VISKASE HOLDINGS's regulatory disclosures and financial reporting.
Viskase Holdings, Inc., formerly Enzon Pharmaceuticals, Inc., completed its merger with Viskase Companies, Inc. and subsequently changed its corporate name. Following this transaction, the Audit Committee appointed Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with unanimous Board ratification, subject to completion of client acceptance procedures.
Grant Thornton previously served as Viskase’s auditor before the merger. As a result of the change, EisnerAmper LLP, Enzon’s prior auditor, was dismissed. EisnerAmper’s reports on the company’s 2024 and 2025 financial statements were unqualified, and the company reports no disagreements or reportable events with EisnerAmper during that period. The company also states it did not consult Grant Thornton on accounting or auditing matters before the appointment.
Viskase Holdings, Inc. has promoted long-time finance executive Michael Blecic to Chief Financial Officer, effective April 10, 2026. Blecic, age 57, has worked at the company’s subsidiary since 1995 and has served as Vice President, Chief Accounting Officer and Treasurer since February 2013, roles he will retain.
The interim Chief Financial Officer engagement with Mackenzie Stender through Silverman Consulting, Inc. ended as of the same date. Viskase also appointed Joseph D. King as Executive Vice President while he continues as Senior Vice President, General Counsel and Secretary. Neither Blecic nor King will receive additional compensation beyond normal annual merit increases for these new titles.